Abstract: The present invention relates to a method for the production and the selection of human or chimæric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).

Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

Abstract: Mammalian prolactin (PRL) variants having a mutation or set of mutations within the 14 N-terminal amino acids that prevent the formation of a disulfide bridge between Cys4 and Cys11 and, a sterically hindering mutation or set of mutations within binding site 2 of PRL. These variants are useful as antagonists of mammalian prolactin receptors (PRLR), more particularly of human prolactin receptor (hPRLR).

Abstract: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.

Abstract: The present invention concerns a method for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) for an individual, wherein said method comprises determining the length of the polyalanine repeat of the protein encoded by at least one allele of the FOXE1 (Forkhead box E1) gene in a tissue sample obtained from said individual; and a kit for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) in an individual comprising at least one nucleic acid probe or oligonucleotide which can be used in such a method.

Abstract: An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B which binds to CD 36.

Abstract: The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine.

Abstract: The invention relates to a method for preparing a heart organotypic slice culture, comprising; a) providing a slice of heart, b) placing the slice of step a) on the upper surface of a semiporous support which is permeable to a culture medium, c) placing the support of step b) onto a culture medium, the slice being fed through the semi-porous support by capillarity.

Abstract: Transfecting compounds which include an aminoglycoside linked to a lipid via a spacer, and their polyguanidylated derivatives are provided. These compounds are useful for the in vitro, ex vivo, or in vivo transfection of nucleic acids into various cell types.

Abstract: The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient.

Abstract: The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.

Abstract: The invention relates to a method for culturing mammalian stem cells, in particular embryonic stem cells comprising the following steps: a) providing a perfused bioreactor (1) comprising a cell culture chamber (2); b) placing said mammalian stem cells within said culture chamber (2); c) providing a perfusion loop which provides fresh medium to said perfused bioreactor and removes used medium from said perfused bioreactor; d) providing a dialysis loop which comprises a reservoir of medium (3) and dialysis chamber (4); wherein the dialysis loop provides fresh medium to the perfusion loop through the dialysis chamber (4). The invention also relates to a device for culturing mammalian stem cells according to the invention.

Abstract: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.

Abstract: The invention relates to human or animal food and more particularly to a food composition for improving digestibility of foodstuff lipids, comprising one or more lysophospholipids and/or phospholipids. The invention further relates to a foodstuff containing said food composition and a method for improving the digestibility of foodstuff lipids.

Abstract: The application relates to antibodies which recognize the AviTag™ peptide of sequence MSGLNDIFEAQKIEWHE (SEQ ID No. 1) and to fragments thereof which recognize SEQ ID No. 1, wherein said antibodies or said fragments thereof recognize polypeptides containing SEQ ID No. 1 at their NH2 terminus and polypeptides containing SEQ ID No. 1 at their COOH terminus. The application further relates to a method for sorting target cells presenting on their surface a surface marker from a mixed cell population comprising the steps of: a) incubating said mixed cell population with a tagged adapter which binds to said surface marker of said target cells, wherein said adapter is bound to an antibody which recognizes said tag, and wherein said antibody is immobilized on a solid support. b) collecting said target cells.

Abstract: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.

Abstract: The present invention relates to a method for filtering the signal of neuronal activity during a high frequency deep brain stimulation (DBS) to remove the stimulus artefact in the observed signal, comprising the step of approximating the observed signal trajectories in phase space the observed signal being considered as a sum of the stimulation artefacts induced by the signal of stimulation, wherein the signal of stimulation is assumed to be a solution of an ordinary differential equation including a self-oscillating system with stable limit cycle; slicing the observed signal and its derivative into segments, each segment corresponding to a period of stimulation; collecting N selected periods of stimulation to a training set; estimating the limit cycle of the self-oscillating system; synchronizing each artefact of the observed signal with the estimated limit cycle; subtracting the estimated limit cycle from each artefact in phase space according to the synchronization; collecting all segments in order to obta

Abstract: The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carried out on animal models of transitory or permanent myocardial ischemia. It was then observed that electrophysiological remodeling and post-ischemic fibrosis were prevented by using caspase-2 specific inhibitors. The invention is then based on the demonstration that caspase-2 and its activation represents an early and transitory step of the cardiac apoptotic mechanisms resulting from a myocardial ischemic and involved in the development of hypertrophy and cardiac insufficiency. The invention thus relates to a method of treatment of cardiovascular pathologies resulting from ischemia by using certain caspase-2 specific inhibitors.

Abstract: A pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The composition can be used to improve in vivo gene transfer.

Abstract: The invention relates to a method for assessing the risk of a cardiovascular disease and/or for diagnosing dyslipidemia in a patient, said method comprising: a) isolating in a blood sample obtained from said patient the high density lipoprotein (HDL) fraction or a subfraction thereof; and b) measuring in said HDL fraction or subfraction thereof the concentration of one or more biomarkers selected from the group consisting of Sphingosine-1-Phosphate (S1P), sphingomyelin (SM) and Apolipoprotein A-I (apoA-1).